Literature DB >> 16764215

Opioid-induced respiratory effects: new data on buprenorphine.

Albert Dahan1.   

Abstract

When selecting the appropriate long-acting opioid to treat cancer pain, both analgesic efficacy and safety need consideration. Generally, opioids are well tolerated. However, of opioid-typical adverse events, respiratory depression is especially important because of the risk of a fatal outcome. Although all potent opioid analgesics act via the micro-opioid receptor system, they differ in how they affect respiratory control. Recently, the respiratory effects of fentanyl (1 7 microg/kg) and buprenorphine (0.7-9 microg g/kg) were compared in healthy opioid-naïve volunteers. Fentanyl produced dose-dependent depression of respiration with apnoea at doses > or = 3 microg/kg, while buprenorphine caused depression that levelled at approximately 50% of baseline with doses > or = 2 microg/kg. These findings indicate the occurrence of a ceiling in the respiratory depression induced by buprenorphine but not by fentanyl. Surprisingly few studies have addressed the clinically important ability to reverse the respiratory effects of opioids. A recent assessment of the naloxone dose required to reverse 0.2 mg intravenous buprenorphine-induced respiratory depression in healthy opioid-naïve volunteers, found that the accumulated naloxone dose causing 50% reversal of respiratory depression was 1.20 +/- 0.32 mg/70 kg (given in 30 min); 80% reversal was observed at 2.50 +/- 0.60 mg/70 kg (given in 30 min). At greater buprenorphine doses, full reversal is observed when the duration of naloxone infusion is increased. These findings indicate the need for a continuous rather than bolus administration of naloxone to reverse the respiratory effects of buprenorphine. In conclusion, buprenorphine is more favourable compared with fentanyl in respect to ventilatory control. Buprenorphine causes limited respiratory depression with a ceiling effect at higher doses, while fentanyl causes dose-dependent respiratory depression with apnoea at high dose levels. In the rare instance of respiratory depression, reversal is possible with a sufficient and continuous infusion of naloxone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764215

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  27 in total

Review 1.  Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

Review 4.  Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

Review 5.  Community use of naloxone for opioid overdose.

Authors:  Marianne E Jauncey; Suzanne Nielsen
Journal:  Aust Prescr       Date:  2017-08-01

Review 6.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

7.  Single use of fentanyl in colonoscopy is safe and effective and significantly shortens recovery time.

Authors:  G Lazaraki; J Kountouras; S Metallidis; S Dokas; T Bakaloudis; D Chatzopoulos; E Gavalas; C Zavos
Journal:  Surg Endosc       Date:  2007-02-16       Impact factor: 4.584

8.  Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Authors:  Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer
Journal:  Pain       Date:  2013-05-07       Impact factor: 6.961

Review 9.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.

Authors:  Matthew J Worley; Keith G Heinzerling; Steven Shoptaw; Walter Ling
Journal:  Exp Clin Psychopharmacol       Date:  2015-08-24       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.